Scotiabank Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $26.00

Keros Therapeutics (NASDAQ:KROS - Get Free Report) had its target price dropped by Scotiabank from $41.00 to $26.00 in a report issued on Monday,Benzinga reports. The firm currently has a "sector outperform" rating on the stock. Scotiabank's price objective suggests a potential upside of 91.20% from the company's current price.

Several other brokerages have also recently issued reports on KROS. HC Wainwright reduced their price target on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday. Oppenheimer reduced their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a research report on Thursday, January 16th. Piper Sandler reduced their price target on shares of Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a research report on Friday, January 17th. Guggenheim reissued a "neutral" rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Finally, Wedbush reissued a "neutral" rating and set a $15.00 price target on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, Keros Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $37.00.

Keros Therapeutics Price Performance

Shares of KROS traded down $0.05 during mid-day trading on Monday, reaching $13.60. The stock had a trading volume of 249,307 shares, compared to its average volume of 822,731. Keros Therapeutics has a 52-week low of $9.12 and a 52-week high of $72.37. The business's fifty day moving average is $12.20 and its 200 day moving average is $24.23. The firm has a market cap of $552.28 million, a price-to-earnings ratio of -2.60 and a beta of 1.32.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $211.25 million for the quarter, compared to analysts' expectations of $84.62 million. During the same quarter in the prior year, the company posted ($1.21) earnings per share. As a group, sell-side analysts anticipate that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the business's stock in a transaction on Wednesday, April 9th. The stock was bought at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the transaction, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. The trade was a 27.01% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 20.60% of the company's stock.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC purchased a new stake in shares of Keros Therapeutics during the first quarter worth about $25,000. CWM LLC grew its holdings in shares of Keros Therapeutics by 10,157.7% during the first quarter. CWM LLC now owns 2,667 shares of the company's stock worth $27,000 after buying an additional 2,641 shares in the last quarter. AlphaQuest LLC grew its holdings in shares of Keros Therapeutics by 469.0% during the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock worth $57,000 after buying an additional 2,964 shares in the last quarter. Virtus ETF Advisers LLC grew its holdings in shares of Keros Therapeutics by 107.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after buying an additional 1,998 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Keros Therapeutics during the fourth quarter worth about $90,000. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.